Article
Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.
The Journal of antimicrobial chemotherapy - 1 Apr 2016
Gubavu Camelia, Prazuck Thierry, Niang Mohamadou, Buret Jennifer, Mille Catherine, Guinard Jérôme, Avettand-Fènoël Véronique, Hocqueloux Laurent
Abstract excerpt
BACKGROUND: Dolutegravir is a powerful, well-tolerated integrase inhibitor with a high genetic barrier to resistance and may thus constitute the backbone of lightened regimens. METHODS: This was a monocentric, retrospective study. HIV-1-infected patients receiving dolutegravir as monotherapy (mDGV) or dual therapy (dDGV) were systematically identified. The primary outcome was the proportion of patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.